Compare Stocks: ANIP, ADMA, ANVS, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.84 +0.8%	$8.96	$7.21 ▼ $20.46	$2.20B	0.74	2.43 million shs	1.48 million shs
ANIP ANI Pharmaceuticals	$75.35 -2.5%	$80.36	$70.15 ▼ $99.50	$1.73B	0.44	363,215 shs	379,118 shs
ANVS Annovis Bio	$1.81 +1.1%	$1.80	$1.54 ▼ $5.50	$77.54M	1.25	602,596 shs	618,557 shs
LQDA Liquidia	$68.62 -3.4%	$79.29	$21.15 ▼ $93.61	$6.14B	0.58	1.62 million shs	1.70 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+3.91%	+17.56%	+19.42%	-43.12%
ANIP ANI Pharmaceuticals	0.00%	-1.55%	-4.05%	-8.91%	-16.85%
ANVS Annovis Bio	0.00%	-1.90%	+3.72%	-19.38%	-27.60%
LQDA Liquidia	0.00%	-7.82%	-22.92%	+12.53%	+150.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.84 +0.8%	$8.96	$7.21 ▼ $20.46	$2.20B	0.74	2.43 million shs	1.48 million shs
ANIP ANI Pharmaceuticals	$75.35 -2.5%	$80.36	$70.15 ▼ $99.50	$1.73B	0.44	363,215 shs	379,118 shs
ANVS Annovis Bio	$1.81 +1.1%	$1.80	$1.54 ▼ $5.50	$77.54M	1.25	602,596 shs	618,557 shs
LQDA Liquidia	$68.62 -3.4%	$79.29	$21.15 ▼ $93.61	$6.14B	0.58	1.62 million shs	1.70 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+3.91%	+17.56%	+19.42%	-43.12%
ANIP ANI Pharmaceuticals	0.00%	-1.55%	-4.05%	-8.91%	-16.85%
ANVS Annovis Bio	0.00%	-1.90%	+3.72%	-19.38%	-27.60%
LQDA Liquidia	0.00%	-7.82%	-22.92%	+12.53%	+150.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.33	Hold	$18.67	89.70% Upside
ANIP ANI Pharmaceuticals	2.50	Moderate Buy	$105.83	40.46% Upside
ANVS Annovis Bio	2.60	Moderate Buy	$11.67	544.57% Upside
LQDA Liquidia	2.45	Hold	$98.08	42.94% Upside

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	LQDA Liquidia	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$79.00 ➝ $92.00
8/12/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$109.00 ➝ $111.00
8/12/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $110.00
8/12/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Hold	$90.00
8/11/2026	ANIP ANI Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/10/2026	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$124.00 ➝ $119.00
8/10/2026	ANIP ANI Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$91.00 ➝ $90.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$512.28M	4.30	$0.65 per share	15.04	$1.82 per share	5.41
ANIP ANI Pharmaceuticals	$883.37M	1.96	$9.94 per share	7.58	$26.00 per share	2.90
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.10) per share	N/A
LQDA Liquidia	$158.32M	38.80	N/A	N/A	$2.18 per share	31.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	14.06	11.58	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
ANIP ANI Pharmaceuticals	$78.34M	$4.64	16.24	8.76	N/A	11.07%	27.37%	10.47%	11/6/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	50.09	15.67	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)

Latest ANIP, ADMA, ANVS, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	$2.21	+$0.17	$1.05	$260.13 million	$266.04 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
ANIP ANI Pharmaceuticals	0.99	2.91	2.41
ANVS Annovis Bio	N/A	3.47	1.27
LQDA Liquidia	0.63	2.31	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ANIP ANI Pharmaceuticals	76.05%
ANVS Annovis Bio	15.83%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
ANIP ANI Pharmaceuticals	8.10%
ANVS Annovis Bio	20.80%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	223.99 million	215.25 million	Optionable
ANIP ANI Pharmaceuticals	600	22.97 million	21.11 million	Optionable
ANVS Annovis Bio	3	42.61 million	33.74 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable

ANIP, ADMA, ANVS, and LQDA Headlines

Recent News About These Companies

Katherine Rielly-Gauvin Sells 18,393 Shares of Liquidia (NASDAQ:LQDA) Stock

August 22 at 7:21 AM | insidertrades.com

Katherine Rielly-Gauvin Sells 18,393 Shares of Liquidia (NASDAQ:LQDA) Stock

August 21 at 5:06 PM | marketbeat.com

Liquidia (NASDAQ:LQDA) Director Katherine Rielly-Gauvin Sells 36,789 Shares of Stock

August 21 at 5:06 PM | marketbeat.com

Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors

August 20 at 8:00 PM | gurufocus.com

Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares

August 20 at 7:06 AM | insidertrades.com

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares of Stock

August 19, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Insider Sells $3,703,000.00 in Stock

August 19, 2026 | marketbeat.com

Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?

August 19, 2026 | zacks.com

Renaissance Technologies LLC Sells 198,753 Shares of Liquidia Corporation $LQDA

August 19, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA

August 18, 2026 | marketbeat.com

LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?

August 17, 2026 | zacks.com

FY2026 EPS Estimates for Liquidia Decreased by HC Wainwright

August 17, 2026 | americanbankingnews.com

FY2026 EPS Estimates for Liquidia Reduced by HC Wainwright

August 17, 2026 | marketbeat.com

HC Wainwright Predicts Liquidia's Q3 Earnings (NASDAQ:LQDA)

August 16, 2026 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Rating Lowered to "Hold" at Zacks Research

August 15, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Stock Price Expected to Rise, Bank of America Analyst Says

August 15, 2026 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Trading Down 6.6% After Earnings Miss

August 15, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)

August 14, 2026 | theglobeandmail.com

HC Wainwright Brokers Lower Earnings Estimates for Liquidia

August 14, 2026 | marketbeat.com

BTIG Research Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

August 14, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and LQDA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.84 +0.08 (+0.82%)

As of 08/21/2026 04:00 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals NASDAQ:ANIP

$75.35 -1.97 (-2.55%)

As of 08/21/2026 04:00 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Annovis Bio NYSE:ANVS

$1.81 +0.02 (+1.12%)

As of 08/21/2026 03:58 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Liquidia NASDAQ:LQDA

$68.62 -2.43 (-3.42%)

As of 08/21/2026 04:00 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIP, ADMA, ANVS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIP, ADMA, ANVS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and LQDA Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

Annovis Bio NYSE:ANVS

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIP, ADMA, ANVS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIP, ADMA, ANVS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and LQDA Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

Annovis Bio NYSE:ANVS

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools